Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO, Büyükberber S, Ozkan M, Alkiş N, Sevinc A, Ozdemir NY, Alici S, Esbah O, Berk V, Camci C, Ulas A, Coskun U, Benekli M; Anatolian Society of Medical Oncology (ASMO). Kaya AO, et al. Among authors: alici s. Asian Pac J Cancer Prev. 2012;13(2):463-7. doi: 10.7314/apjcp.2012.13.2.463. Asian Pac J Cancer Prev. 2012. PMID: 22524807 Free article.
Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
Karaoglu A, Arslan UY, Ozkan M, Kalender ME, Alici S, Coskun U, Gumus M, Celenkoglu G, Er O, Sevinc A, Buyukberber S, Alkis N, Benekli M; Anatolian Society of Medical Oncology. Karaoglu A, et al. Among authors: alici s. Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):63-6. Asian Pac J Cancer Prev. 2009. PMID: 19469626 Free article. Clinical Trial.
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.
Yildiz R, Kalender ME, Dane F, Sevinc A, Gumus M, Camci C, Alici S, Kaya AO, Yaman E, Ozturk B, Coskun U, Benekli M, Uncu D, Buyukberber S. Yildiz R, et al. Among authors: alici s. J Oncol Pharm Pract. 2010 Sep;16(3):173-8. doi: 10.1177/1078155209347402. Epub 2009 Oct 15. J Oncol Pharm Pract. 2010. PMID: 19833685
Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, Dayan A, Demir L, Geredeli C, Kocer M, Arslan UY, Inal A, Unal OU, Mert AG, Bilici M, Ozkan M, Elkiran ET, Yaman S, Durnalı AG, Suner A, Alici S, Tarhan MO, Boruban C, Urakci Z, Buyukberber S. Kaplan MA, et al. Among authors: alici s. Oncology. 2012;83(3):141-50. doi: 10.1159/000338782. Epub 2012 Jul 18. Oncology. 2012. PMID: 22814315
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
Kaya AO, Coskun U, Ozkan M, Sevinc A, Yilmaz AU, Gumus M, Unal OU, Ozdemir NY, Alici S, Berk V, Degerli H, Oner MK, Ozturk C, Kefeli U, Camcı C; Anatolian Society of Medical Oncology (ASMO). Kaya AO, et al. Among authors: alici s. Onkologie. 2012;35(10):576-80. doi: 10.1159/000342674. Epub 2012 Sep 18. Onkologie. 2012. PMID: 23038228
Clinicopathological features in bilateral breast cancer.
Baykara M, Ozturk SC, Buyukberber S, Helvaci K, Ozdemir N, Alkis N, Berk V, Koca D, Coskun U, Oksuzoglu B, Uncu D, Arpaci E, Ustaalioglu BO, Demirci U, Kucukoner M, Dogu GG, Alici S, Akman T, Ozkan M, Aslan UY, Durnali AG, Benekli M. Baykara M, et al. Among authors: alici s. Asian Pac J Cancer Prev. 2012;13(9):4571-5. doi: 10.7314/apjcp.2012.13.9.4571. Asian Pac J Cancer Prev. 2012. PMID: 23167382 Free article.
50 results